Table 1 Characteristics of included studies
Study | Country | Patients (N) | NMBAs | Experimental intervention | Control intervention | Ventilation Strategy | Definition of ARDS |
|---|---|---|---|---|---|---|---|
Gainnier 2004 [17] | France | 56 | Cisatracurium | A bolus of 50 mg followed by 5 μg∙kg− 1∙ min− 1 infusion for 48 h. | An infusion of saline at a rate of 4 mL/h | Volume-assist/control (6–8 mL/kg) | American-European consensus definition (PaO2:FIO2 ratio < 150, PEEP ≥5 cm H2O) |
Forel 2006 [18] | France | 36 | Cisatracurium | A bolus of 0.2 mg/kg followed by 5 μg∙kg− 1∙ min− 1 infusion for 48 h. | An infusion of saline at a rate of 4 mL/h | Volume-assist/control (4–8 mL/kg), plateau pressure of < 30 cm H2O | American-European consensus definition (PaO2:FIO2 ratio < 200, PEEP ≥5 cm H2O) |
Papazian 2010 [9] | France | 339 | Cisatracurium | A bolus of 15 mg followed by 37.5 mg per hour for 48 h. | A bolus of 15 mg placebo followed 37.5 mg per hour for 48 h. | Volume-assist/control (6–8 mL/kg), plateau pressure of < 32 cm H2O | American-European consensus definition (PaO2:FIO2 ratio < 150, PEEP ≥5 cm H2O) |
Lyu 2014 [20] | China | 96 | Vecuronium | A bolus of 0.1 mg∙kg − 1 followed by 0.05 mg∙kg− 1∙h− 1 for 24~ 48 h. | Usual treatment | Volume-assist/control (4–8 mL/kg), plateau pressure of < 30~35 cm H2O | The Berlin definition (PaO2: FIO2 ratio < 200, PEEP ≥5 cm H2O) |
Guervilly 2017 [19] | France | 24 | Cisatracurium | A bolus of 15 mg followed by 37.5 mg per hour for 48 h | Usual treatment | Volume-assist/control (6 mL/kg) | The Berlin definition (PaO2: FIO2 ratio < 150, PEEP ≥5 cm H2O) |
ROSE 2019 [16] | USA | 1006 | Cisatracurium | A bolus of 15 mg followed by 37.5 mg per hour for 48 h | Usual treatment | Volume-assist/control (6 mL/kg) | (PaO2:FIO2 ratio < 150, PEEP ≥8 cm H2O) |